SG11201810763TA - Anti-coagulation factor xi antibodies - Google Patents
Anti-coagulation factor xi antibodiesInfo
- Publication number
- SG11201810763TA SG11201810763TA SG11201810763TA SG11201810763TA SG11201810763TA SG 11201810763T A SG11201810763T A SG 11201810763TA SG 11201810763T A SG11201810763T A SG 11201810763TA SG 11201810763T A SG11201810763T A SG 11201810763TA SG 11201810763T A SG11201810763T A SG 11201810763TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- new jersey
- california
- rule
- avenue
- Prior art date
Links
- 108010074864 Factor XI Proteins 0.000 title abstract 2
- 230000010100 anticoagulation Effects 0.000 title abstract 2
- 239000003114 blood coagulation factor Substances 0.000 title abstract 2
- 230000004913 activation Effects 0.000 abstract 3
- 241000221096 Simmondsia chinensis Species 0.000 abstract 2
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 abstract 1
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 abstract 1
- 102100030563 Coagulation factor XI Human genes 0.000 abstract 1
- 101710161089 Coagulation factor XI Proteins 0.000 abstract 1
- HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 abstract 1
- HEVGGTGPGPKZHF-UHFFFAOYSA-N Epilaurene Natural products CC1C(=C)CCC1(C)C1=CC=C(C)C=C1 HEVGGTGPGPKZHF-UHFFFAOYSA-N 0.000 abstract 1
- 108010071241 Factor XIIa Proteins 0.000 abstract 1
- 101001062768 Homo sapiens Coagulation factor XI Proteins 0.000 abstract 1
- 108010094028 Prothrombin Proteins 0.000 abstract 1
- 102100027378 Prothrombin Human genes 0.000 abstract 1
- 108090000190 Thrombin Proteins 0.000 abstract 1
- 229960003886 apixaban Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 229960003850 dabigatran Drugs 0.000 abstract 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 abstract 1
- 229960000622 edoxaban Drugs 0.000 abstract 1
- 230000006624 extrinsic pathway Effects 0.000 abstract 1
- 230000006623 intrinsic pathway Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229940039716 prothrombin Drugs 0.000 abstract 1
- 229960001148 rivaroxaban Drugs 0.000 abstract 1
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 abstract 1
- 229960004072 thrombin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111111111111111111111111113311111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2017/218371 Al 21 December 2017 (21.12.2017) WIP0 I PCT (51) International Patent Classification: FERT, Dietmar [US/US]; 12 Village Ct., Lawrence Town- C07K16/36 (2006.01) A61K 39/00 (2006.01) ship, New Jersey 08648 (US). (21) International Application Number: (72) Inventors; and PCT/US2017/036940 (71) Applicants (for NZ, US only): GANTI, Vaishnavi (22) International Filing Date: [IN/US]; 901 S. California Avenue, Palo Alto, California 12 June 2017 (12.06.2017) 94304 (US). TABRIZIFARD, Mohammad [US/US]; 901 S. California Avenue, Palo Alto, California 94304 (US). (25) Filing Language: English (74) Common Representative: MERCK SHARP & DOHME (26) Publication Language: English CORP.; 126 East Lincoln Avenue, Rahway, New Jersey (30) Priority Data: 07065-0907 (US). 62/349,888 14 June 2016 (14.06.2016) US (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (71) Applicant (for all designated States except US): MERCK AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, SHARP & DOHME CORP. [US/US]; 126 East Lincoln CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, Avenue, Rahway, New Jersey 07065-0907 (US). DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (72) Inventors; and HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, — (71) Applicants (for US only): CHEN, Zhu [US/US]; 5 Nor- KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, mandy Ct., Warren, New Jersey 07059 (US). ELLS- MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, WORTH, Kenneth, P. [US/US]; 2000 Galloping Hill OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, Road, Kenilworth, New Jersey 07033 (US). MILLIGAN, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, James [US/US]; 30 Lauren Lane, New Egypt, New Jersey TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = 08533 (US). OLDHAM, Elizabeth [US/US]; 901 S. Cal- (84) Designated States (unless otherwise indicated, for every ifornia Avenue, Palo Alto, California 94304 (US). SEIF- kind of regional protection available): ARIPO (BW, GH, = Title: ANTI-COAGULATION FACTOR XI ANTIBODIES (54) Intrinsic pathway = contact mAb -- activation = = .1 = FXII FX1la = Extrinsic pathway = Da FXIa Z` . 1F—FV1la = = = FIX FIXa = = r .° FV111 FXa 1-1 .4 Rivaroxaban FVa 1-1 IN apixaban Prothrombin Thrombin edoxaban en Go ,-, el Dabigatran FIG. 1A Clot IN 11 0 (57) : Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation N factor XIIa as well as activation of FIX by FXIa are described. C [Continued on next page] WO 2017/218371 Al MIDEDIMOMOIDEIRMEM00111fillifiliNEVOIMIE GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(U)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349888P | 2016-06-14 | 2016-06-14 | |
| PCT/US2017/036940 WO2017218371A1 (en) | 2016-06-14 | 2017-06-12 | Anti-coagulation factor xi antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810763TA true SG11201810763TA (en) | 2018-12-28 |
Family
ID=59078269
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810763TA SG11201810763TA (en) | 2016-06-14 | 2017-06-12 | Anti-coagulation factor xi antibodies |
| SG10202103120UA SG10202103120UA (en) | 2016-06-14 | 2017-06-12 | Anti-coagulation factor xi antibodies |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202103120UA SG10202103120UA (en) | 2016-06-14 | 2017-06-12 | Anti-coagulation factor xi antibodies |
Country Status (28)
| Country | Link |
|---|---|
| US (6) | US10676536B2 (en) |
| EP (1) | EP3469002A1 (en) |
| JP (2) | JP7022081B2 (en) |
| KR (2) | KR102218714B1 (en) |
| CN (2) | CN109476758B (en) |
| AR (1) | AR108717A1 (en) |
| AU (3) | AU2017286432B2 (en) |
| BR (1) | BR112018075858A2 (en) |
| CA (2) | CA3025869A1 (en) |
| CL (1) | CL2018003565A1 (en) |
| CO (1) | CO2018013434A2 (en) |
| CR (1) | CR20180583A (en) |
| DO (1) | DOP2018000284A (en) |
| EA (1) | EA201892716A1 (en) |
| EC (1) | ECSP18091593A (en) |
| GE (1) | GEP20227382B (en) |
| IL (1) | IL263272A (en) |
| JO (1) | JOP20180121A1 (en) |
| MA (1) | MA45234A (en) |
| MX (1) | MX2018015757A (en) |
| MY (1) | MY201852A (en) |
| NI (1) | NI201800134A (en) |
| PE (1) | PE20190416A1 (en) |
| PH (1) | PH12018502586A1 (en) |
| SG (2) | SG11201810763TA (en) |
| TN (1) | TN2018000417A1 (en) |
| TW (2) | TWI802193B (en) |
| WO (1) | WO2017218371A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200312A1 (en) | 2015-06-26 | 2017-06-16 | Novartis Ag | Factor xi antibodies and methods of use |
| TW201802121A (en) | 2016-05-25 | 2018-01-16 | 諾華公司 | Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof |
| KR102218714B1 (en) * | 2016-06-14 | 2021-02-24 | 머크 샤프 앤드 돔 코포레이션 | Anticoagulant factor XI antibody |
| BR112019012667A2 (en) | 2016-12-23 | 2020-02-11 | Novartis Ag | FACTOR XI ANTIBODIES AND METHODS OF USE |
| CN110423278B (en) * | 2019-08-08 | 2020-07-17 | 上海博槿生物科技有限公司 | Antibody against activated form factor XIa of anticoagulant factor XI and preparation method and application thereof |
| CN117487016A (en) * | 2020-07-02 | 2024-02-02 | 北京拓界生物医药科技有限公司 | anti-FXI/FXIa antibodies, antigen binding fragments thereof and medical application thereof |
| AU2021302199A1 (en) * | 2020-07-03 | 2023-02-23 | Suzhou Alphamab Co., Ltd. | Coagulation factor XI (FXI) binding protein |
| CN117480182A (en) * | 2021-02-09 | 2024-01-30 | 艾瑞克斯疗法有限公司 | anti-S100A 4 humanized antibodies, uses and methods |
| WO2023098637A1 (en) * | 2021-11-30 | 2023-06-08 | 苏州康宁杰瑞生物科技有限公司 | Method for preventing and/or treating thromboembolic diseases |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| JP2749167B2 (en) | 1988-06-21 | 1998-05-13 | ジェネンテク，インコーポレイテッド | Methods and therapeutic compositions for the treatment of myocardial infarction |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2108048T3 (en) | 1990-08-29 | 1997-12-16 | Genpharm Int | PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES. |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ATE207080T1 (en) | 1991-11-25 | 2001-11-15 | Enzon Inc | MULTIVALENT ANTIGEN-BINDING PROTEINS |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| JPH0656382A (en) | 1992-08-04 | 1994-03-01 | Kawasaki Steel Corp | Lifting beam unit of bucket winding machine in coke dry quencher |
| MA24512A1 (en) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | PROCESS FOR THE PREPARATION OF ANTICOAGULATING AGENTS USEFUL IN THE TREATMENT OF THROMBOSIS |
| GB9818110D0 (en) | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
| US6096002A (en) | 1998-11-18 | 2000-08-01 | Bioject, Inc. | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method |
| MXPA01005515A (en) | 1998-12-01 | 2003-07-14 | Protein Design Labs Inc | Humanized antibodies to gamma-interferon. |
| AU778392B2 (en) | 2000-03-03 | 2004-12-02 | Cambridge Antibody Technology Limited | Human antibodies against eotaxin and their use |
| WO2003080672A1 (en) | 2002-03-22 | 2003-10-02 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| TWI382031B (en) | 2003-07-15 | 2013-01-11 | Amgen Inc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
| CN101120087A (en) | 2004-12-21 | 2008-02-06 | 森托科尔公司 | Anti-il-12 antibodies, epitopes, compositions, methods and uses |
| US8318906B2 (en) | 2005-04-15 | 2012-11-27 | The Regents Of The University Of California | EMP2 antibodies and their therapeutic uses |
| CA2607147C (en) | 2005-05-09 | 2018-07-17 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| JP5252635B2 (en) | 2005-07-01 | 2013-07-31 | メダレックス インコーポレーティッド | Human monoclonal antibody against programmed death ligand 1 (PD-L1) |
| EA017491B1 (en) | 2005-12-08 | 2012-12-28 | Медарекс, Инк. | Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies |
| SG177194A1 (en) | 2005-12-08 | 2012-01-30 | Medarex Inc | Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and methods for using anti-ptk7 antibodies |
| CA2654502C (en) | 2006-06-06 | 2015-07-14 | Crucell Holland B.V. | Human binding molecules having killing activity against enterococci and uses thereof |
| ES2746925T3 (en) | 2006-08-03 | 2020-03-09 | Medimmune Ltd | Antibodies Directed Towards alfaVbeta6 and Use of Them |
| CL2007002567A1 (en) | 2006-09-08 | 2008-02-01 | Amgen Inc | ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN. |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| EP2134749B1 (en) | 2007-03-22 | 2013-11-06 | The Regents of the University of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| GB0708585D0 (en) | 2007-05-03 | 2007-06-13 | Queen Mary & Westfield College | Novel antibody and use in diagnosis and therapy of arthropathies |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| MX344415B (en) | 2007-09-14 | 2016-12-15 | Adimab Inc | Rationally designed, synthetic antibody libraries and uses therefor. |
| SI2207809T1 (en) | 2007-09-26 | 2013-11-29 | U3 Pharma Gmbh | Heparin-binding epidermal growth factor-like growth factor antigen binding proteins |
| SI3002298T1 (en) | 2007-11-21 | 2019-12-31 | Oregon Health & Science University | Anti-factor xi monoclonal antibodies and methods of use thereof |
| US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
| ES2702365T3 (en) * | 2008-06-19 | 2019-02-28 | Prothix Bv | Use of anti-factor XI antibodies for the prevention or treatment of thrombus formation |
| CA2732003A1 (en) | 2008-07-31 | 2010-02-04 | James D. Marks | Antibodies that neutralize botulinum neurotoxins |
| NZ603824A (en) | 2008-10-31 | 2013-11-29 | Centocor Ortho Biotech Inc | Toll-like receptor 3 antagonists |
| WO2010054007A1 (en) | 2008-11-07 | 2010-05-14 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| DK2373691T3 (en) | 2008-12-18 | 2019-04-15 | Oregon Health&Science Univ | ANTI-FXI ANTIBODIES AND PROCEDURES FOR USE |
| CA2748158A1 (en) | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | Targeted binding agents directed to .alpha.5.beta.1 and uses thereof |
| AU2010226392B9 (en) | 2009-03-20 | 2014-05-22 | Amgen Inc. | Selective and potent peptide inhibitors of Kv1.3 |
| US8722860B2 (en) | 2009-04-16 | 2014-05-13 | Abbvie Biotherapeutics Inc. | Anti-TNF-α antibodies and their uses |
| HUE025966T2 (en) | 2009-04-27 | 2016-05-30 | Kyowa Hakko Kirin Co Ltd | Anti-il-3ra antibody for use in treatment of blood tumor |
| US8435516B2 (en) | 2009-10-12 | 2013-05-07 | Pfizer Inc. | Cancer treatment |
| WO2011056997A1 (en) | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
| ES2776980T3 (en) | 2009-12-23 | 2020-08-03 | Merck Sharp & Dohme | 3M cell line |
| US20110244826A1 (en) * | 2010-02-03 | 2011-10-06 | Subramaniyan Krishnan | Mobile communication plan offerings |
| WO2012009568A2 (en) | 2010-07-16 | 2012-01-19 | Adimab, Llc | Antibody libraries |
| CA2815154A1 (en) | 2010-08-06 | 2012-02-09 | U3 Pharma Gmbh | Use of her3 binding agents in prostate treatment |
| WO2012068540A2 (en) | 2010-11-19 | 2012-05-24 | Toshio Imai | Neutralizing anti-ccl20 antibodies |
| KR102169651B1 (en) | 2011-01-06 | 2020-10-23 | 다이액스 코포레이션 | Plasma kallikrein binding proteins |
| SG193956A1 (en) | 2011-04-01 | 2013-11-29 | Sloan Kettering Inst Cancer | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 |
| ES2693647T3 (en) | 2011-06-06 | 2018-12-13 | Novo Nordisk A/S | Therapeutic antibodies |
| US8765385B2 (en) | 2011-10-27 | 2014-07-01 | Ravindra Kumar | Method of detection of neutralizing anti-actriib antibodies |
| ES2588484T3 (en) | 2012-04-13 | 2016-11-03 | Rottapharm Biotech S.R.L. | Anti-ADAMTS-5 antibody, derivatives and uses thereof |
| DK2847228T3 (en) | 2012-05-10 | 2018-11-19 | Bayer Pharma AG | ANTIBODIES THAT CAN BIND TO COAGULATION FACTOR XI AND / OR ITS ACTIVATED FORM FACTOR XIA, AND APPLICATIONS THEREOF |
| WO2013173255A2 (en) | 2012-05-17 | 2013-11-21 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind egfr |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| JP6527508B2 (en) | 2013-10-01 | 2019-06-05 | メディミューン リミテッド | Methods for treating and diagnosing cancers that overexpress αVβ6 |
| US20170107273A1 (en) | 2014-03-20 | 2017-04-20 | Japan As Represented By Director-General Of National Institute Of Infectious Diseases | Antibody having infection-inhibiting activity against hepatitis c virus |
| RU2764981C1 (en) | 2014-06-03 | 2022-01-24 | ИксБиотеч Инк. | Compositions and methods for treating and preventing infections caused by staphylococcus aureus |
| EA201790342A1 (en) | 2014-08-08 | 2017-07-31 | ЭЛЕКТОР ЭлЭлСи | ANTIBODIES TO TREM2 AND METHODS OF THEIR APPLICATION |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| CA2981851A1 (en) | 2015-04-07 | 2016-10-13 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
| WO2016201389A2 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| JOP20200312A1 (en) | 2015-06-26 | 2017-06-16 | Novartis Ag | Factor xi antibodies and methods of use |
| WO2017015619A1 (en) | 2015-07-23 | 2017-01-26 | The Regents Of The University Of California | Antibodies to coagulation factor xia and uses thereof |
| EP3356415B1 (en) | 2015-09-29 | 2024-05-01 | Amgen Inc. | Asgr inhibitors for reduzing cholesterol levels |
| JOP20170013B1 (en) | 2016-01-22 | 2021-08-17 | Merck Sharp & Dohme | Anti-coagulation factor xi antibodies |
| KR102218714B1 (en) * | 2016-06-14 | 2021-02-24 | 머크 샤프 앤드 돔 코포레이션 | Anticoagulant factor XI antibody |
| CA3037087A1 (en) | 2016-09-20 | 2018-03-29 | Bayer Pharma Aktiengesellschaft | Antibodies against factor xi and uses thereof |
-
2017
- 2017-06-12 KR KR1020197001266A patent/KR102218714B1/en active IP Right Grant
- 2017-06-12 MA MA045234A patent/MA45234A/en unknown
- 2017-06-12 CN CN201780037421.3A patent/CN109476758B/en active Active
- 2017-06-12 SG SG11201810763TA patent/SG11201810763TA/en unknown
- 2017-06-12 TN TNP/2018/000417A patent/TN2018000417A1/en unknown
- 2017-06-12 BR BR112018075858-2A patent/BR112018075858A2/en unknown
- 2017-06-12 SG SG10202103120UA patent/SG10202103120UA/en unknown
- 2017-06-12 CN CN202310501882.9A patent/CN116425879A/en active Pending
- 2017-06-12 PE PE2018003203A patent/PE20190416A1/en unknown
- 2017-06-12 TW TW110149482A patent/TWI802193B/en active
- 2017-06-12 TW TW106119391A patent/TWI752964B/en active
- 2017-06-12 AU AU2017286432A patent/AU2017286432B2/en active Active
- 2017-06-12 JP JP2018565042A patent/JP7022081B2/en active Active
- 2017-06-12 MY MYPI2018002406A patent/MY201852A/en unknown
- 2017-06-12 US US15/619,620 patent/US10676536B2/en active Active
- 2017-06-12 CA CA3025869A patent/CA3025869A1/en active Pending
- 2017-06-12 WO PCT/US2017/036940 patent/WO2017218371A1/en unknown
- 2017-06-12 EP EP17731444.0A patent/EP3469002A1/en active Pending
- 2017-06-12 GE GEAP201714983A patent/GEP20227382B/en unknown
- 2017-06-12 CA CA3172367A patent/CA3172367A1/en active Pending
- 2017-06-12 MX MX2018015757A patent/MX2018015757A/en unknown
- 2017-06-12 EA EA201892716A patent/EA201892716A1/en unknown
- 2017-06-12 CR CR20180583A patent/CR20180583A/en unknown
- 2017-06-12 AR ARP170101603A patent/AR108717A1/en unknown
- 2017-06-12 KR KR1020217004608A patent/KR102379580B1/en active IP Right Grant
- 2017-06-16 JO JOP/2018/0121A patent/JOP20180121A1/en unknown
-
2018
- 2018-11-25 IL IL263272A patent/IL263272A/en unknown
- 2018-12-06 PH PH12018502586A patent/PH12018502586A1/en unknown
- 2018-12-10 NI NI201800134A patent/NI201800134A/en unknown
- 2018-12-11 CL CL2018003565A patent/CL2018003565A1/en unknown
- 2018-12-11 EC ECSENADI201891593A patent/ECSP18091593A/en unknown
- 2018-12-12 CO CONC2018/0013434A patent/CO2018013434A2/en unknown
- 2018-12-13 DO DO2018000284A patent/DOP2018000284A/en unknown
-
2020
- 2020-05-01 US US16/864,570 patent/US11512142B2/en active Active
- 2020-05-01 US US16/864,559 patent/US11661460B2/en active Active
- 2020-05-01 US US16/864,583 patent/US11479615B2/en active Active
- 2020-05-01 US US16/864,577 patent/US11485794B2/en active Active
- 2020-07-30 AU AU2020210233A patent/AU2020210233B2/en active Active
-
2021
- 2021-03-26 JP JP2021053470A patent/JP7277500B2/en active Active
-
2023
- 2023-04-18 US US18/302,033 patent/US20230287141A1/en active Pending
-
2024
- 2024-02-20 AU AU2024201084A patent/AU2024201084A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810763TA (en) | Anti-coagulation factor xi antibodies | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201804787UA (en) | Human immunodeficiency virus neutralizing antibodies | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201906161VA (en) | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
| SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201810777WA (en) | Purification of multispecific antibodies | |
| SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201408153YA (en) | Prostate-specific membrane antigen antibody drug conjugates | |
| SG11201407561UA (en) | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | |
| SG11201804127SA (en) | Ctla4 binders | |
| SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
| SG11201407537YA (en) | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer | |
| SG11201906319XA (en) | Compositions and methods for the depletion of cd137+ cells | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201809252YA (en) | Methods for determining dpp3 and therapeutic methods | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations |